EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real-world clinical outcomes of anticancer treatments in patients with advanced melanoma in China: retrospective, observational study

Chuanliang Cui, Xieqiao Yan, Shusen Liu, Anne C. Deitz, Lu Si, Zhihong Chi, Xinan Sheng, Bin Lian, Jianfeng Li, Jun Ge, Xuan Wang, Lili Mao und 7 weitere

International Journal of Surgery Oncology · 2019-11 · 4 (6) · e76-e76

DOI: 10.1097/ij9.0000000000000076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Surgery Oncology, 2019-11. Verfasst von Chuanliang Cui und 18 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Treatment options for advanced melanoma in China are lacking, particularly second-line therapies. The aim of this retrospective observational study was to describe the real-world effectiveness of available anticancer therapies in patients with locally advanced/metastatic melanoma in China.

Methods

Adult patients with unresectable stage III or IV melanoma treated between January 1, 2014, and December 31, 2015, at the Beijing Cancer Hospital (BCH) were eligible (data cutoff: December 31, 2017). Data were obtained from patient electronic medical records. Responders were adjudicated per Response Evaluation Criteria in Solid Tumors, version 1.1. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method.

Results

Of 248 eligible patients, 221 and 116 were treated with anticancer therapies in first-line and second-line settings, respectively (89 received both at BCH). Approximately 95% of patients had stage IV melanoma; 40.7% had acral melanoma, and 30.6% had mucosal histology. By data cutoff, 195 of 248 (78.6%) patients had died. Median OS for all patients was 10.5 months; 12-month OS rate was 43.9%. In the first-line setting, the objective response rate was 6.3% (95% confidence interval, 3.5%–10.4%) and the median duration of response was 9.1 months. Median PFS was 3.5 months and 12-month PFS rate was 10.6%; median OS was 10.5 months and 12-month OS rate was 43.5%. In the second-line setting, objective response rate was 3.4% (95% confidence interval, 0.9%–8.6%) and median duration of response was 7.5 months. Median PFS was 2.3 months and 12-month PFS rate was 5.2%; median OS was 7.5 months and 12-month OS rate was 30.5%.

Conclusion

In China, first-line and second-line anticancer therapy seems to be associated with suboptimal clinical outcomes in advanced melanoma, indicating a need for effective therapies.

Zitieren

APA

Cui, C., Yan, X., Liu, S., Deitz, A. C., Si, L., Chi, Z., Sheng, X., Lian, B., Li, J., Ge, J., Wang, X., Mao, L., Tang, B., Zhou, L., Bai, X., Li, S., Li, B., Wu, H., & Guo, J. (2019). Real-world clinical outcomes of anticancer treatments in patients with advanced melanoma in China: retrospective, observational study. International Journal of Surgery Oncology, 4(6), e76-e76. https://doi.org/10.1097/ij9.0000000000000076

Vancouver

Cui C, Yan X, Liu S, Deitz AC, Si L, Chi Z, et al. Real-world clinical outcomes of anticancer treatments in patients with advanced melanoma in China: retrospective, observational study. International Journal of Surgery Oncology. 2019;4(6):e76-e76. doi:10.1097/ij9.0000000000000076

BibTeX
@article{Cui2019,
  author = {Cui, Chuanliang and Yan, Xieqiao and Liu, Shusen and Deitz, Anne C. and Si, Lu and Chi, Zhihong and Sheng, Xinan and Lian, Bin and Li, Jianfeng and Ge, Jun and Wang, Xuan and Mao, Lili and Tang, Bixia and Zhou, Li and Bai, Xue and Li, Siming and Li, Ben and Wu, Haiyan and Guo, Jun},
  title = {Real-world clinical outcomes of anticancer treatments in patients with advanced melanoma in China: retrospective, observational study},
  journal = {International Journal of Surgery Oncology},
  year = {2019},
  volume = {4},
  number = {6},
  pages = {e76--e76},
  doi = {10.1097/ij9.0000000000000076}
}
Kostenlos starten →